4D Molecular Therapeutics (FDMT) Total Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Total Liabilities data on file, last reported at $61.1 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $61.1 million, up 32.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.1 million (up 32.74% YoY), and the FY2025 annual result was $61.0 million, up 22.64% from the prior year.
• Total Liabilities was little changed at $61.1 million in Q1 2026 per FDMT's latest filing, from $61.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $61.1 million in Q1 2026 and troughed at $25.4 million in Q1 2023.
• A 5-year average of $39.6 million and a median of $31.8 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 112.9% in 2022, then retreated 11.97% in 2023.
• A 5-year view of Total Liabilities shows it stood at $30.5 million in 2022, then gained by 5.09% to $32.1 million in 2023, then jumped by 55.26% to $49.8 million in 2024, then climbed by 22.64% to $61.0 million in 2025, then increased by 0.04% to $61.1 million in 2026.
• Business Quant data shows FDMT's Total Liabilities at $61.1 million in Q1 2026, $61.0 million in Q4 2025, and $55.0 million in Q3 2025.